Ubamatamab
- Generic Name
- Ubamatamab
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Phase 2
Not yet recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT06787612
Phase II Trial of Ubamatamab Alone or in Combination with Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Phase 2
Recruiting
- Conditions
- SMARCB1-Deficient Malignancies
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06444880
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
Phase 1
Recruiting
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 612
- Registration Number
- NCT04590326
- Locations
- 🇫🇷
Hopital Lyon Sud, Pierre-Benite, Lyon, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇺🇸The City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Phase 1
Recruiting
- Conditions
- Recurrent Primary Peritoneal CancerRecurrent Endometrial CancerRecurrent Ovarian CancerRecurrent Fallopian Tube Cancer
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 690
- Registration Number
- NCT03564340
- Locations
- 🇬🇧
Guys Hospital, London, United Kingdom
🇮🇱Sharet Institute of Oncology, Jerusalem, Israel
🇺🇸University of Alabama_6th Ave, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath